

## **InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2024 Annual General Meeting**

**October 30, 2023 - InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2024 Annual General Meeting. The responsibility of the Nomination Committee is to present to the 2024 Annual General Meeting proposals regarding election of the Chairman of the Board and other members of the Board, fees and any other remuneration to the members of the Board as well as election and remuneration of the auditors.**

The Nomination Committee for the 2024 Annual General Meeting of InDex Pharmaceuticals Holding AB (publ) consists of:

- Karl Tobieson, appointed by Linc
- Ivo Staijen, appointed by HBM Healthcare Investments
- Jan Särilvik, appointed by Fjärde AP-fonden
- Björn Wasing, appointed by SEB-Stiftelsen and S-E-Bankens Utvecklingsstiftelse
- Wenche Rolfsen, Chairman of the Board (convener)

The Nomination Committee together represents approximately 38 percent of all voting rights in the company as of September 30, 2023.

Shareholders wishing to submit comments or proposals to the Nomination Committee can send them via email to [info@indexpharma.com](mailto:info@indexpharma.com).

### **For more information:**

Jenny Sundqvist, CEO

Phone: +46 8 122 038 50

E-mail: [jenny.sundqvist@indexpharma.com](mailto:jenny.sundqvist@indexpharma.com)

Johan Giléus, CFO and deputy CEO

Phone: +46 8 122 038 50

E-mail: [joan.gileus@indexpharma.com](mailto:joan.gileus@indexpharma.com)

### **Publication**

The information was submitted for publication through the agency of the contact person set out above at 08:10 CET on October 30, 2023.

### **InDex Pharmaceuticals in brief**

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company's lead asset is the drug candidate cobitolimod, which is being evaluated in the phase III program CONCLUDE as a novel treatment of moderate to severe left-sided ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company's shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm. Redeye AB is the company's Certified Adviser. For more information, please visit [www.indexpharma.com](http://www.indexpharma.com).

*The information in this press release is intended for investors.*